 Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results from a Phase 2 trial involving its new lung cancer drug combinations. The results showed the program is viable but left investors questioning how the pair and their proposed therapeutic could compete against other more established companies in the tough research and development space. 